Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 17/20 | 0.55 |
| ▸ | CDK2 | P24941 | 17/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 17/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22494745 | 0.99 | CCNE1 (0.54) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22494744 | 0.99 | CCNE1 (0.54) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL22523005 | 0.85 | CCNE1 (0.54) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL24246502 | 0.82 | SMN1; SMN2 (0.61) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20883077 | 0.82 | SMN1; SMN2 (0.66) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20883052 | 0.82 | SMN1; SMN2 (0.66) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20877568 | 0.82 | SMN1; SMN2 (0.55) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL20877569 | 0.82 | SMN1; SMN2 (0.55) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL26087016 | 0.82 | CCNE1 (0.54) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL26087015 | 0.82 | CCNE1 (0.54) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | CCNE1 3461/4885CDK2 1919/4885CDK5 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.